Press Releases

Koneksa Announces Partnership with Beacon Biosignals for Clinical Trials in Sleep and Neurologic Disorders Using EEG Biomarkers

Koneksa has announced a partnership with Beacon Biosignals, a computational neurodiagnostics company, to launch a clinical trial to investigate the integration of Beacon’s at-home electroencephalogram (EEG) into the Koneksa Neuroscience Solution Toolkit. The Beacon platform unlocks longitudinal, at-home EEG technology, applies machine-learning algorithms to maximize insights into brain activity, and empowers sponsors with comprehensive data analysis and data visualization capabilities. The Koneksa-sponsored clinical validation study, “A basket observational study to determine usability, analytical validity, clinical validity, and biomarker discovery for at-home EEG, wearable, and mobile device...

Xealth Is Honored In 25th Anniversary Digital Health Awards®

McKesson Ventures portfolio company Xealth was selected as a winner in the 25th anniversary Digital Health Awards® program. This competition recognizes the best digital health resources. “Shaping Your Digital Health Future” received a Gold Award for Connected Digital Health: Consumer Directed Digital Health Programs. “Digital solutions are becoming an integral part of care delivery and Xealth is the only digital health platform that takes an approach that has driven improved activation, engagement, and operational efficiency for our health system clients,” said Xealth Co-Founder and CEO Mike McSherry....

RxLightning Closes $17.5M Series A to Accelerate Growth and Remove Barriers to Essential Specialty Medications

McKesson Ventures has participated in a $17.5 million Series A round for RxLightning, a platform for streamlining access and affordability for specialty medications. This brings the total the company has raised since its inception to $20.5 million. With RxLightning, healthcare providers—from those practicing at independent clinics to large health systems—leverage a streamlined workflow to complete the multi-step specialty medication onboarding process in a matter of minutes. The company’s MedAccess Ecosystem is an integrated platform that provides transparency into the patient access and affordability journey for doctors,...

Aster Insights Announces that The University of Kansas Cancer Center will join the Oncology Research Information Network (ORIEN)

Aster Insights, a provider of technology-enabled data and analytics solutions for oncology discovery, has announced that The University of Kansas Cancer Center will join its Oncology Research Information Exchange Network (ORIEN). The KU Cancer Center is the latest NCI-designated cancer center to join ORIEN, which is comprised of 18 cancer centers across the U.S. dedicated to collaborative research to accelerate cancer discovery and development. Launched in 2014, Aster Insights’ ORIEN platform is the largest and longest-running academic cancer research consortium of its kind in the United...

ORIEN Member Presentations at 2023 ASCO Demonstrate Unique Value of Aster Insights’ Data

Aster Insights has announced its participation as a research partner at the American Society of Clinical Oncology (ASCO) Annual Meeting June 2-6, 2023, in Chicago. An oral presentation and three posters will be presented at this year’s ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the company’s Oncology Research Information Exchange Network® (ORIEN) AVATAR program. These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN. “We are thrilled to be selected for these diverse presentations...

Private AI and Replica Analytics announce partnership to tackle data privacy

Replica Analytics, an Aetion company, is partnering with data privacy software solutions developer Private AI. The partnership is a response to an urgent need for a privacy-preserving solution in healthcare and aims to provide a comprehensive solution for healthcare’s data privacy and security challenges. Replica Analytics’ pioneering software, Replica Synthesis 3.0, generates synthetic structured data, in the place of real data, making healthcare data safe to use in medical research and for other valuable insights. Private AI’s technology accurately detects and removes personally identifiable information from...

Aster Insights Names Dr. Anand Shah as Chief Executive Officer

Aster Insights has announced the appointment of Dr. Anand Shah as chief executive officer, effective immediately. He succeeds Jim Gabriele, who has stepped down from his position. Gabriele and Shah have collaborated closely on a number of strategic, operational, and business development initiatives over the past six months, and they will continue to work together to ensure a smooth leadership transition. As CEO, Dr. Shah will lead the company’s continued growth with a focus on advancing Aster Insights’ national academic research collaborations, developing novel discovery products...

Twist Bioscience and Aster Insights Partner on Launch of Next Generation Oncology Panel for Cancer Research

Twist Bioscience Corporation, a company that offers high-quality synthetic DNA using its silicon platform, along with Aster Insights, has announced the availability of the AsterExome panel, which can simultaneously enable whole exome sequencing (WES) with additional coverage for target regions known to contain 620 genes associated with cancer. By integrating the panel into Aster Insights’ AVATAR sequencing program, AsterExome can provide comprehensive analysis in the discovery research market for solid tumor and heme malignancy samples. “This new panel, built with Twist’s design expertise and custom [next-generation...

Clinical ink Announces New Continuous Glucose Monitoring Solution

Clinical Ink, a global life science technology company, now offers continuous glucose monitoring (CGM) within its integrated digital biomarker solution. The new modules enable remote collection, central storage, and analysis of sensor data from commercially available devices for use in diabetes clinical trials. The solution addresses device connectivity status, providing robust, on-device CGM data collection in both offline and online scenarios with efficient data synchronization management when connected. This integration is facilitated by the recent FDA clearance of commercial CGM devices, which include the Abbott FreeStyle...

RCT-DUPLICATE Findings Demonstrate Capability of Real-World Evidence Studies to Reach Conclusions Similar to Randomized Clinical Trials

Real-world evidence (RWE) technology and analytics company Aetion has announced the culmination of the RCT-DUPLICATE demonstration project, with complete findings published in The Journal of the American Medical Association (JAMA). This three-year initiative tested whether researchers asking clinical questions in real-world data (RWD)—data from patients’ day-to-day interactions with the healthcare system—would obtain similar results to findings from randomized clinical trials (RCTs). In cases where clinical trial designs aligned with real patient care processes, the RWE studies and RCTs came to largely similar conclusions. As part of...